Hepatitis C News and Research

Latest Hepatitis C News and Research

Biota Holdings reports total revenue of $61.7M for half-year of 2009

Biota Holdings Limited today announced a half year net profit after tax of $33.5 million, (1H F09: $7.2m). Profit before tax was $41.4 million (1H F09: $10.1m) benefiting significantly from an increase in Relenza royalties.

16 Feb 2010

Merck announces global sales of $27.4 billion for full-year 2009

Merck & Co., Inc. today announced financial results for the fourth quarter and the full year of 2009 which include the results of legacy Schering-Plough operations from the close of the merger on Nov. 3, 2009 through Dec. 31, 2009.

16 Feb 2010

PAN to provide co-payment assistance for medications to underinsured patients through five new funds

Patient Access Network Foundation will expand its services to provide co-payment assistance for medications to underinsured patients through five new funds -- including grants of up to $10,000 per year for prostate cancer patients.

12 Feb 2010

Mayo Clinic Health Letter features comprehensive coverage of the liver

The liver, the largest internal organ, is the body's ultimate multitasker. While the liver is not glamorous or sentimental -- there are no love songs about a broken liver -- it simultaneously plays a key role in the body's metabolic, digestive and regulatory systems.

12 Feb 2010

New screening system developed to discover molecules that block HCV life cycle

A newly designed system of identifying molecules for treating hepatitis C should enable scientists to discover novel and effective therapies for the dangerous and difficult-to-cure disease of the liver, says Zhilei Chen, a Texas A&M University assistant professor of chemical engineering who helped develop the screening system.

12 Feb 2010

Biomagnetics Diagnostics to accelerate development of assay test cartridge for malaria, HIV/AIDS, hepatitis and TB

Biomagnetics Diagnostics Corp., a developer of revolutionary diagnostic systems and technology for malaria, HIV/AIDS, hepatitis, tuberculosis and detection, announced today the implementation of a program to accelerate the availability of the world's first Integrated Optical BioSensor (IOBS) platform. The Company is currently reviewing research and manufacturing partnerships to develop simple to replicate bench top versions of the IOBS platform on which single pathogen or multiple pathogen testing assay cartridges can be developed.

11 Feb 2010

PLAN C Agency launches Hepatitis B awareness campaign in the West Coast

PLAN C Agency, in collaboration with biopharmaceutical company Gilead Sciences, launched a Hepatitis B awareness campaign titled "B HERE" at three college campuses in the West Coast. The goal was to raise the much needed awareness regarding the rising epidemic of Hepatitis B among Asian Americans and educate the youth on the importance of getting tested.

11 Feb 2010

Top ten myths about sex

Boston Medical Group, a national physician network specializing in the treatment of erectile dysfunction and premature ejaculation, today released ten of the top myths surrounding sex. From which gender spends the most time fantasizing to whether size really matters, the list covers some of the common misconceptions about time spent between the sheets.

10 Feb 2010

STDUniversity.org launches interactive, personalized STD test recommendation

STDUniversity.org is the first website to provide an interactive, personalized STD test recommendation developed by academic and medical experts. This expert-based tool incorporates screening guidelines from the Centers for Disease Control and Prevention (CDC), U.S. Agency for Healthcare Research and Quality (AHRQ), and the U.S. Preventive Service Task Force (USPSTF).

10 Feb 2010

sanofi-aventis reports 2009 fourth-quarter and full-year net earnings

Commenting on the Group's 2009 performance, sanofi-aventis Chief Executive Officer Christopher A. Viehbacher said, "2009 was the first year of implementation of our new strategy. Major steps have already been achieved in strengthening our growth platforms and reinforcing our R&D pipeline while delivering a double-digit EPS(1) growth".

10 Feb 2010

Study explores link between HBV genotype C and liver cirrhosis

Hepatitis B virus (HBV) genotypes have distinct geographical distributions, and have been shown to differ with regard to clinical outcome and prognosis. However, the relationship between HBV genotypes and liver cirrhosis remains controversial and no study on exploring the association between HBV genotypes and subclinical cirrhosis in community-based population has been reported.

10 Feb 2010

IgM/IgG ratio is useful in diagnosing primary biliary cirrhosis

Previous studies have shown that assessment of immunoglobulin subclasses in plasma cells by immunohistochemistry (IHC) may be useful in the histopathologic evaluation of autoimmune liver diseases. However, further studies are necessary in order to validate the diagnostic utility of IgM and IgG immunohistochemistry in this specific scenario.

10 Feb 2010

Thymosin β4 exhibits potential as new therapeutic agent for liver failure due to chronic HBV infection

REGENERX BIOPHARMACEUTICALS, INC. announced today that researchers have correlated Tβ4 levels with the clinical course of patients with hepatitis B virus-related liver failure. It was reported that serum thymosin β4 levels were significantly lower in patients with chronic hepatitis B infection and that the magnitude of the reduction of thymosin β4 was closely related to the severity of the hepatic injury and to patient death. Since patients with higher Tβ4 levels survived the disease, changes in Tβ4 values could reflect outcome in some liver failure patients.

9 Feb 2010

Debiopharm Group signs exclusive licence agreement with Novartis for alisporivir

Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, today announced the signature of an exclusive licence agreement with Novartis for the development, manufacture and commercialisation of Debio 025 (alisporivir), a selective, first-in-class cyclophilin (Cyp) inhibitor with a potent anti-hepatitis C virus (HCV) effect. The product is currently in phase 2b clinical development for the treatment of hepatitis C. Debiopharm granted Novartis worldwide commercialisation rights to Debio 025 except for Japan.

9 Feb 2010

Two U.S. insurers approve coverage of radioembolization for treatment of unresectable liver cancer

MDS Nordion, a global leader in providing products and services for medical imaging and radiotherapeutics, today announced that two of the largest health insurers in the United States have recently approved coverage of radioembolization to treat unresectable liver cancer, which includes the use of MDS Nordion's TheraSphere(R) treatment. The two insurance companies and their affiliates together serve more than one-quarter of Americans and do business in all 50 states.

6 Feb 2010

Biota Holdings reports Relenza sales, indicative royalties for three months ended 31 December 2009

Biota Holdings Limited today announced that it had received written notification from GlaxoSmithKline that Relenza sales were $462 million and indicative royalties were $32.6 million, for the three months ended 31 December 2009.

5 Feb 2010

Progenics Pharmaceuticals to present preclinical data of multiplex PI3K inhibitors

Progenics Pharmaceuticals, Inc. today announced the presentation of preclinical data on a series of novel compounds that simultaneously blocked two critical pathways involved in the growth and survival of cancer cells.

4 Feb 2010

Global cancer rates could be reduced by 40% with prevention strategies, report says

"Forty percent of the 12 million people diagnosed with cancer worldwide each year could avert the killer disease by protecting themselves against infections and changing their lifestyles, experts said on Tuesday," Reuters reports.

4 Feb 2010

Closing funding gap for federal viral hepatitis education, screening and surveillance programs stops liver cancer

With most liver cancer caused by undetected or untreated hepatitis B or C viral infection, the 22,000 new cases of liver cancer that are diagnosed each year could be dramatically reduced if Congress took decisive action to close the funding gap for federal viral hepatitis education, screening, and surveillance programs, the National Viral Hepatitis Roundtable (NVHR) said today.

4 Feb 2010

RECOTHROM topical hemostat exhibits low rate of anti-product antibody formation

ZymoGenetics, Inc., today announced the publication of pooled safety and immunogenicity observations from eight clinical trials of RECOTHROM in the February issue of the Journal of the American College of Surgeons. The authors concluded that RECOTHROM is a well-tolerated topical hemostatic agent in numerous surgical settings and has a low rate of anti-product antibody formation. In the pooled data from all trials, less than one percent of treated patients developed product-specific antibodies. None of the antibodies neutralized native coagulation proteins.

2 Feb 2010

Hepatitis C News and Research

Latest Hepatitis C News and Research

Biota Holdings reports total revenue of $61.7M for half-year of 2009

Merck announces global sales of $27.4 billion for full-year 2009

PAN to provide co-payment assistance for medications to underinsured patients through five new funds

Mayo Clinic Health Letter features comprehensive coverage of the liver

New screening system developed to discover molecules that block HCV life cycle

Biomagnetics Diagnostics to accelerate development of assay test cartridge for malaria, HIV/AIDS, hepatitis and TB

PLAN C Agency launches Hepatitis B awareness campaign in the West Coast

Top ten myths about sex

STDUniversity.org launches interactive, personalized STD test recommendation

sanofi-aventis reports 2009 fourth-quarter and full-year net earnings

Study explores link between HBV genotype C and liver cirrhosis

IgM/IgG ratio is useful in diagnosing primary biliary cirrhosis

Thymosin β4 exhibits potential as new therapeutic agent for liver failure due to chronic HBV infection

Debiopharm Group signs exclusive licence agreement with Novartis for alisporivir

Two U.S. insurers approve coverage of radioembolization for treatment of unresectable liver cancer

Biota Holdings reports Relenza sales, indicative royalties for three months ended 31 December 2009

Progenics Pharmaceuticals to present preclinical data of multiplex PI3K inhibitors

Global cancer rates could be reduced by 40% with prevention strategies, report says

Closing funding gap for federal viral hepatitis education, screening and surveillance programs stops liver cancer

RECOTHROM topical hemostat exhibits low rate of anti-product antibody formation

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Hepatitis C News and Research

Latest Hepatitis C News and Research

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Newsletters you may be interested in